Clinical pharmacist‐led costs optimization in ischaemic stroke care: A diagnosis‐related groups‐based intervention study
This study aimed to evaluate the impact of clinical pharmacists' intervention on drug cost optimization for ischaemic stroke inpatients under the diagnosis-related groups (DRGs) payment model. This study collected hospitalization data of patients with ischaemic stroke in the BR23 disease group...
Saved in:
| Published in: | British journal of clinical pharmacology Vol. 91; no. 12; p. 3529 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
21.08.2025
|
| Subjects: | |
| ISSN: | 0306-5251, 1365-2125, 1365-2125 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | This study aimed to evaluate the impact of clinical pharmacists' intervention on drug cost optimization for ischaemic stroke inpatients under the diagnosis-related groups (DRGs) payment model.
This study collected hospitalization data of patients with ischaemic stroke in the BR23 disease group from the neurology department between June 2023 and July 2024. The dataset was divided into a control group (no pharmacist intervention) and an experimental group (pharmacist intervention). Using t-tests, chi-square tests and Mann-Whitney U tests, this study analysed the changing trends in hospitalization costs for ischaemic stroke patients after pharmacists participated in clinical pharmacy pathways under the DRG model. The analysis included demographic characteristics, comorbidities, length of hospitalization, incidence of adverse drug reactions, irrational medication use rates, total hospitalization costs, total drug costs and costs of key monitoring drugs between the 2 groups.
There were no significant differences in age, sex, or comorbidities. Length of hospitalization and incidence of adverse drug reactions did not differ significantly (P > .05), but irrational medication use was lower in the experimental group (P < .05). Compared to the control group, the experimental group had significantly lower total hospitalization costs, total drug costs and costs of key monitoring drugs (P < .05), along with clear improvements in cost control and excess payment management.
This study demonstrates that pharmacist involvement in clinical pathways under the DRGs payment model effectively reduces drug costs for hospitalized ischaemic stroke patients while ensuring clinical efficacy and safety, highlighting the role of pharmacists in cost control. |
|---|---|
| AbstractList | This study aimed to evaluate the impact of clinical pharmacists' intervention on drug cost optimization for ischaemic stroke inpatients under the diagnosis-related groups (DRGs) payment model.AIMSThis study aimed to evaluate the impact of clinical pharmacists' intervention on drug cost optimization for ischaemic stroke inpatients under the diagnosis-related groups (DRGs) payment model.This study collected hospitalization data of patients with ischaemic stroke in the BR23 disease group from the neurology department between June 2023 and July 2024. The dataset was divided into a control group (no pharmacist intervention) and an experimental group (pharmacist intervention). Using t-tests, chi-square tests and Mann-Whitney U tests, this study analysed the changing trends in hospitalization costs for ischaemic stroke patients after pharmacists participated in clinical pharmacy pathways under the DRG model. The analysis included demographic characteristics, comorbidities, length of hospitalization, incidence of adverse drug reactions, irrational medication use rates, total hospitalization costs, total drug costs and costs of key monitoring drugs between the 2 groups.METHODSThis study collected hospitalization data of patients with ischaemic stroke in the BR23 disease group from the neurology department between June 2023 and July 2024. The dataset was divided into a control group (no pharmacist intervention) and an experimental group (pharmacist intervention). Using t-tests, chi-square tests and Mann-Whitney U tests, this study analysed the changing trends in hospitalization costs for ischaemic stroke patients after pharmacists participated in clinical pharmacy pathways under the DRG model. The analysis included demographic characteristics, comorbidities, length of hospitalization, incidence of adverse drug reactions, irrational medication use rates, total hospitalization costs, total drug costs and costs of key monitoring drugs between the 2 groups.There were no significant differences in age, sex, or comorbidities. Length of hospitalization and incidence of adverse drug reactions did not differ significantly (P > .05), but irrational medication use was lower in the experimental group (P < .05). Compared to the control group, the experimental group had significantly lower total hospitalization costs, total drug costs and costs of key monitoring drugs (P < .05), along with clear improvements in cost control and excess payment management.RESULTSThere were no significant differences in age, sex, or comorbidities. Length of hospitalization and incidence of adverse drug reactions did not differ significantly (P > .05), but irrational medication use was lower in the experimental group (P < .05). Compared to the control group, the experimental group had significantly lower total hospitalization costs, total drug costs and costs of key monitoring drugs (P < .05), along with clear improvements in cost control and excess payment management.This study demonstrates that pharmacist involvement in clinical pathways under the DRGs payment model effectively reduces drug costs for hospitalized ischaemic stroke patients while ensuring clinical efficacy and safety, highlighting the role of pharmacists in cost control.CONCLUSIONSThis study demonstrates that pharmacist involvement in clinical pathways under the DRGs payment model effectively reduces drug costs for hospitalized ischaemic stroke patients while ensuring clinical efficacy and safety, highlighting the role of pharmacists in cost control. This study aimed to evaluate the impact of clinical pharmacists' intervention on drug cost optimization for ischaemic stroke inpatients under the diagnosis-related groups (DRGs) payment model. This study collected hospitalization data of patients with ischaemic stroke in the BR23 disease group from the neurology department between June 2023 and July 2024. The dataset was divided into a control group (no pharmacist intervention) and an experimental group (pharmacist intervention). Using t-tests, chi-square tests and Mann-Whitney U tests, this study analysed the changing trends in hospitalization costs for ischaemic stroke patients after pharmacists participated in clinical pharmacy pathways under the DRG model. The analysis included demographic characteristics, comorbidities, length of hospitalization, incidence of adverse drug reactions, irrational medication use rates, total hospitalization costs, total drug costs and costs of key monitoring drugs between the 2 groups. There were no significant differences in age, sex, or comorbidities. Length of hospitalization and incidence of adverse drug reactions did not differ significantly (P > .05), but irrational medication use was lower in the experimental group (P < .05). Compared to the control group, the experimental group had significantly lower total hospitalization costs, total drug costs and costs of key monitoring drugs (P < .05), along with clear improvements in cost control and excess payment management. This study demonstrates that pharmacist involvement in clinical pathways under the DRGs payment model effectively reduces drug costs for hospitalized ischaemic stroke patients while ensuring clinical efficacy and safety, highlighting the role of pharmacists in cost control. |
| Author | Zhang, Jin Li, Xianlin Li, Yun Guo, Haitao Zheng, Xiaojun |
| Author_xml | – sequence: 1 givenname: Yun surname: Li fullname: Li, Yun organization: Department of Pharmacy The First Hospital of Shanxi Medical University Taiyuan Shanxi China – sequence: 2 givenname: Xianlin surname: Li fullname: Li, Xianlin organization: School of Pharmacy Shanxi Medical University Taiyuan Shanxi China – sequence: 3 givenname: Haitao surname: Guo fullname: Guo, Haitao organization: Department of Pharmacy The First Hospital of Shanxi Medical University Taiyuan Shanxi China – sequence: 4 givenname: Jin surname: Zhang fullname: Zhang, Jin organization: Department of Neurology The First Hospital of Shanxi Medical University Taiyuan Shanxi China – sequence: 5 givenname: Xiaojun orcidid: 0009-0001-0535-5076 surname: Zheng fullname: Zheng, Xiaojun organization: Department of Pharmacy The First Hospital of Shanxi Medical University Taiyuan Shanxi China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40836872$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9kctKxTAQhoMoerwsfAHpUhfV3Jq07uTgDQQ3ui5pMtVo29QkFY4L8RF8Rp_EeI4KA8MM3_ww_7-N1gc3AEL7BB8TjOlJo8djiSkXa2hGmChySmixjmaYYZEXtCBbaDuEJ4wJI6LYRFscl0yUks7Q-7yzg9Wqy8ZH5XulbYhfH58dmEy7EEPmxmh7-6aidUNmUwX9qKC3OgvRu2fItPJwmp1lxqqHwQUb0rmHTsUk8eDdNP4sGhXSaIcI_hWGpVaIk1nsoo1WdQH2fvsOur84v5tf5Te3l9fzs5tcUy5jLk2pTEVbZqqiNC3mLaVcc0wb0gjdSMnAABcVF4wLkEYpIFJXTMuyAmE020GHK93Ru5cJQqz79Ah0nRrATaFmyTyOJRcyoQe_6NT0YOrR2175Rf3nWQKOVoD2LgQP7T9CcP2TR53yqJd5sG-kzYKp |
| Cites_doi | 10.3390/antibiotics11030381 10.1136/svn‐2019‐000242 10.1111/bcp.14709 10.3390/healthcare13040349 10.1007/s11096‐019‐00888‐2 10.1055/s‐0041‐1722916 10.1038/s41572‐019‐0118‐8 10.3233/thc‐240284 10.2147/rmhp.S417672 10.3389/fpubh.2024.1339504 10.2147/ceor.S227934 10.1016/j.heliyon.2023.e14345 10.1186/s12913‐023‐10151‐0 10.3389/fpubh.2024.1425716 10.1080/20523211.2024.2361320 10.1111/jep.13209 10.1016/j.sapharm.2024.06.002 10.2147/rmhp.S463276 10.7189/jogh.11.08007 10.1007/s11096‐021‐01356‐6 |
| ContentType | Journal Article |
| Copyright | 2025 British Pharmacological Society. |
| Copyright_xml | – notice: 2025 British Pharmacological Society. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1002/bcp.70246 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1365-2125 |
| ExternalDocumentID | 40836872 10_1002_bcp_70246 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Shanxi Province High-Quality Development Research Special Project on the Big Health Industry (Key Project) grantid: DJKZXKT2023180 |
| GroupedDBID | --- .3N .GA 05W 0R~ 10A 1OC 23N 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANLZ AAONW AAXRX AAYCA AAYXX AAZKR ABCQN ABCUV ABOCM ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFWVQ AFZJQ AGHNM AGXDD AGYGG AHBTC AIACR AIAGR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALVPJ AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CITATION CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HGLYW HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O8X O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ TEORI TR2 UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WQJ WVDHM WXI WXSBR XG1 YFH YOC YUY ZZTAW ~IA ~WT .55 .GJ .Y3 2WC 31~ 3O- 53G AASGY ABEML ACSCC ALUQN CAG CGR COF CUY CVF DIK ECM EIF EJD EMOBN EX3 GX1 HF~ HYE LW6 NPM WOW X7M ZGI ZXP 7X8 |
| ID | FETCH-LOGICAL-c247t-7d8ad92f3d958df04f224c402b1b6cb773ede46946346e7daae17c93c789e6dc3 |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001555593000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0306-5251 1365-2125 |
| IngestDate | Sat Nov 01 14:16:50 EDT 2025 Thu Nov 27 01:51:53 EST 2025 Sat Nov 29 07:36:10 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | cost control clinical pathways pharmacists neurology diagnosis‐related groups |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2025 British Pharmacological Society. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c247t-7d8ad92f3d958df04f224c402b1b6cb773ede46946346e7daae17c93c789e6dc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0009-0001-0535-5076 |
| PMID | 40836872 |
| PQID | 3246407467 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3246407467 pubmed_primary_40836872 crossref_primary_10_1002_bcp_70246 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-08-21 |
| PublicationDateYYYYMMDD | 2025-08-21 |
| PublicationDate_xml | – month: 08 year: 2025 text: 2025-08-21 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | British journal of clinical pharmacology |
| PublicationTitleAlternate | Br J Clin Pharmacol |
| PublicationYear | 2025 |
| References | e_1_2_11_10_1 e_1_2_11_21_1 e_1_2_11_20_1 e_1_2_11_14_1 e_1_2_11_13_1 e_1_2_11_9_1 e_1_2_11_12_1 e_1_2_11_11_1 e_1_2_11_22_1 e_1_2_11_7_1 e_1_2_11_18_1 e_1_2_11_6_1 e_1_2_11_17_1 e_1_2_11_5_1 e_1_2_11_16_1 e_1_2_11_4_1 e_1_2_11_15_1 e_1_2_11_3_1 e_1_2_11_2_1 e_1_2_11_19_1 Busse R (e_1_2_11_8_1) 2019 |
| References_xml | – ident: e_1_2_11_20_1 doi: 10.3390/antibiotics11030381 – ident: e_1_2_11_3_1 doi: 10.1136/svn‐2019‐000242 – ident: e_1_2_11_22_1 doi: 10.1111/bcp.14709 – ident: e_1_2_11_17_1 doi: 10.3390/healthcare13040349 – ident: e_1_2_11_16_1 doi: 10.1007/s11096‐019‐00888‐2 – ident: e_1_2_11_11_1 doi: 10.1055/s‐0041‐1722916 – ident: e_1_2_11_2_1 doi: 10.1038/s41572‐019‐0118‐8 – ident: e_1_2_11_14_1 doi: 10.3233/thc‐240284 – ident: e_1_2_11_19_1 doi: 10.2147/rmhp.S417672 – ident: e_1_2_11_21_1 doi: 10.3389/fpubh.2024.1339504 – ident: e_1_2_11_6_1 doi: 10.2147/ceor.S227934 – ident: e_1_2_11_15_1 doi: 10.1016/j.heliyon.2023.e14345 – ident: e_1_2_11_13_1 doi: 10.1186/s12913‐023‐10151‐0 – ident: e_1_2_11_5_1 doi: 10.3389/fpubh.2024.1425716 – ident: e_1_2_11_18_1 doi: 10.1080/20523211.2024.2361320 – ident: e_1_2_11_10_1 doi: 10.1111/jep.13209 – ident: e_1_2_11_12_1 doi: 10.1016/j.sapharm.2024.06.002 – ident: e_1_2_11_7_1 doi: 10.2147/rmhp.S463276 – volume-title: Improving healthcare quality in Europe: characteristics, effectiveness and implementation of different strategies year: 2019 ident: e_1_2_11_8_1 – ident: e_1_2_11_4_1 doi: 10.7189/jogh.11.08007 – ident: e_1_2_11_9_1 doi: 10.1007/s11096‐021‐01356‐6 |
| SSID | ssj0013165 |
| Score | 2.4663196 |
| Snippet | This study aimed to evaluate the impact of clinical pharmacists' intervention on drug cost optimization for ischaemic stroke inpatients under the... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database |
| StartPage | 3529 |
| SubjectTerms | Aged Aged, 80 and over Diagnosis-Related Groups - economics Drug Costs - statistics & numerical data Drug-Related Side Effects and Adverse Reactions - economics Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - prevention & control Female Hospitalization - economics Hospitalization - statistics & numerical data Humans Ischemic Stroke - drug therapy Ischemic Stroke - economics Length of Stay - economics Length of Stay - statistics & numerical data Male Middle Aged Pharmacists - economics Pharmacists - organization & administration Pharmacy Service, Hospital - economics Pharmacy Service, Hospital - organization & administration Professional Role |
| Title | Clinical pharmacist‐led costs optimization in ischaemic stroke care: A diagnosis‐related groups‐based intervention study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40836872 https://www.proquest.com/docview/3246407467 |
| Volume | 91 |
| WOSCitedRecordID | wos001555593000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1365-2125 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013165 issn: 0306-5251 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwELZYxwMviN_rgMkg1KdlJM4Px7xNY2NCValQJoWnyLFdKWKkoWmn8t9ztpM0XUEaD0hVVJ1SJ8r31Tmf775D6B28ZUI_59xRcQ4LFOEzh7t85khPUvDHXU-F0jSboJNJnKZs2gRzatNOgJZlvF6z6r9CDTYAW5fO_gPc3aBggO8AOhwBdjjeCfizttaxsqrUgKNzrXTxWq33BmCK-NHUXupYR1HrtHmdIF8vF_PvykhV23J1abPwitoxBS8whCkBqR395pNGaKLLltyo1N4SS-opU4hbN7YV0B-brIJvq3LbkAJ7r4vO-GllIruXvFjy-U7M-3NzYhPEIKGOytrK6GbeNcl2nq2BPlG7tp2Z3irH5qI6oeBm_EFNe_Ilu7gaj7PkPE1G1U9HNxrTG_JN15U9tE9oyOIB2v_4FU7cbD15pv9od_VWjsol77urbTsxf1mZGA8leYQeNksLfGop8RjdU-UTNJrah_3rGCebUrv6GI_wtAfDU7RueYO3eYMNb3CfN7iAT8sbbHmDNW8-4FO8wxrcZw3uswYb1jxDVxfnydml07TlcAQJ6NKhMuaSkZkvWRjLmRvMwA0UgUtyL49ETqmvpAoiFkR-ECkqOVceFcwXNGYqksJ_jgblvFQHCDPhExkJGQVMBT7Jc8FoGAoeci-XkesP0dv2OWeVVV_JrM42yQCMzIAxRG9aBDKYG_WGFy_VfFVnsFjQ-9TgCwzRCwtNN0ygZdljSg7v8OuX6MGGtK_QYLlYqdfovriBP9LiCO3RND5qaPQbdICYQA |
| linkProvider | Wiley-Blackwell |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+pharmacist-led+costs+optimization+in+ischaemic+stroke+care%3A+A+diagnosis-related+groups-based+intervention+study&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Li%2C+Yun&rft.au=Li%2C+Xianlin&rft.au=Guo%2C+Haitao&rft.au=Zhang%2C+Jin&rft.date=2025-08-21&rft.issn=1365-2125&rft.eissn=1365-2125&rft_id=info:doi/10.1002%2Fbcp.70246&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon |